YWYanting Wu

Yanting Wu

*This is an algorithmically generated author record based on publicly available information.

Yanting Wu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Alpha-ketoglutarate ameliorates systemic sclerosis-associated fibrosis by restoring endothelial function

    by Yanting Wu, Shikai Ye, Huanling Chen, Jiahui Li, Xiang Pan, Huajuan Yan, Haiyan Chu, Qingmei Liu, Xiangzhen Kong, Jun Bian, et al.

  • Open Access

    Alpha-Ketoglutarate Ameliorates Systemic Sclerosis-Associated Fibrosis by Restoring Endothelial Function and Metabolic Homeostasis

    by Yanting Wu, Shikai Ye, Huanling Chen, Jiahui Li, Xiang Pan, Huajuan Yan, Xiangzhen Kong, Haiyan Chu, Qingmei Liu, Jun Bian, et al.

    Background: Systemic sclerosis (SSc) is a devastating autoimmune disease characterized by multi‑organ fibrosis with limited therapeutic options.Methods: Using targeted metabolomics, we first observed that α‑KG, a key TCA‑cycle intermediate, was paradoxically elevated in bleomycin‑induced fibrotic lungs and in TGF‑β‑stimulated fibroblasts, prompting us to test whether exogenous supplementation could augment this compensatory response. We administered oral α‑KG in bleomycin‑induced skin and lung fibrosis mouse models.Findings: Oral α‑KG significantly attenuated dermal and pulmonary collagen deposition, reduced inflammatory infiltration, and improved survival. Integrated single‑cell RNA sequencing and bulk transcriptomic deconvolution unexpectedly identified endothelial cells as the predominant cellular target. α‑KG restored endothelial proportions in vivo, rescued angiogenic function and barrier integrity (CD31, eNOS, tight junctions) in HUVECs, suppressed TGF‑β/Smad activation, reversed metabolic repression, including fatty acid oxidation and mitochondrial ultrastructure defects, and upregulated NRF1.Interpretation: Collectively, these findings reveal that α‑KG exerts broad anti‑fibrotic effects by protecting endothelial function and inhibiting pro‑fibrotic signaling, highlighting its potential as a translatable metabolic therapeutic strategy for SSc.

  • Retraction
    Open Access

    Retracted: MicroRNA-1179 regulates proliferation and chemosensitivity of human ovarian cancer cells by targeting the PTEN-mediated PI3K/AKT signaling pathway

    by Zhang Zhihong, Chen Rubin, Lu Liping, Mao Anpeng, Guo Hui, Wu Yanting, Shan Zhenxiu

    [This retracts the article DOI: 10.5114/aoms.2019.86798.].

  • Open Access

    β-Caryophyllene Acts as a Ferroptosis Inhibitor to Ameliorate Experimental Colitis

    by Yan-Ting Wu, Li-Shan Zhong, Chen Huang, Yu-Ying Guo, Fu-Jun Jin, Yu-Ze Hu, Zi-Bo Zhao, Zhe Ren, Yi-Fei Wang

    Macrophage infiltration is one of the main pathological features of ulcerative colitis (UC) and ferroptosis is a type of nonapoptotic cell death, connecting oxidative stress and inflammation. However, whether ferroptosis occurs in the colon macrophages of UC mice and whether targeting macrophage ferroptosis is an effective approach for UC treatment remain unclear. The present study revealed that macrophage lipid peroxidation was observed in the colon of UC mice. Subsequently, we screened several main components of essential oil from Artemisia argyi and found that β-caryophyllene (BCP) had a good inhibitory effect on macrophage lipid peroxidation. Additionally, ferroptotic macrophages were found to increase the mRNA expression of tumor necrosis factor alpha (Tnf-α) and prostaglandin-endoperoxide synthase 2 (Ptgs2), while BCP can reverse the effects of inflammation activated by ferroptosis. Further molecular mechanism studies revealed that BCP activated the type 2 cannabinoid receptor (CB2R) to inhibit macrophage ferroptosis and its induced inflammatory response both in vivo and in vitro. Taken together, BCP potentially ameliorated experimental colitis inflammation by inhibiting macrophage ferroptosis. These results revealed that macrophage ferroptosis is a potential therapeutic target for UC and identified a novel mechanism of BCP in ameliorating experimental colitis.


  • Open Access

    Subacute toxicological evaluation of AT‑533 and AT‑533 gel in Sprague‑Dawley rats

    by Yanting Wu, Xiaowei Song, Shurong Qin, Pengxiao Chen, Lianzhou Huang, Qiaoli Wang, Tianhao Shan, Feng Liang, Xiaofeng Liao, Qiuying Liu, et al.

    As a novel heat shock protein 90 inhibitor, AT‑533 exhibits various biological activities in vitro, including anti‑viral, anti‑tumor and anti‑inflammatory activities. Moreover, AT‑533 gel, a gel dosage form of AT‑533, has been suggested to have anti‑keratitis and herpes simplex virus type‑1 infection‑induced effects on the skin lesions of animals. However, the safety evaluation of AT‑533 and AT‑533 gel has, to the best of our knowledge, not been examined in in vivo toxicological tests. Therefore, these toxicological tests were carried out in the present study. A 30‑day subacute toxicity test for AT‑533 was conducted at doses of 1, 2 and 4 mg/kg in Sprague‑Dawley rats, while that for AT‑533 gel was conducted using a single dose of 5 g/kg. The toxicological tests showed that a high‑dose of AT‑533 caused lethality and side effects in Sprague‑Dawley rats. However, no mortality, loss of appetite and body weight, adverse reactions, or toxicologically relevant alterations in hematology, biochemistry and macroscopic findings (except for skin) occurred in rats exposed to low‑dose AT‑533 and single‑dose AT‑533 gel (5 g/kg) during a 30‑day subacute dermic toxicity study. The aforementioned results suggested that AT‑533 gel is non‑toxic for Sprague‑Dawley rats, as shown by a dermic subacute toxicity test and that except for slight skin irritation, AT‑533 gel had almost no side effects when administered percutaneously for 30 days.